“It wasn’t supposed to be like this: Eisai and Biogen’s new Alzheimer’s disease drug Leqembi was supposed to be the chosen one after the flop that was Biogen and Eisai’s Aduhelm, but neurologists are voicing “frustration” at core elements of the therapy’s rollout.
That’s according to a stark new report out by life sciences consultants at Spherix that delved down into insights from 75 high-prescribing U.S. neurologists that work with Alzheimer’s patients.
The picture painted by them is bleak: Now around six months after the launch of Leqembi, “few surveyed neurologists consider Leqembi to be a significant medical advance over other historical AD treatments,” Spherix’s analysis found.”
Wait till you see the "danger" of Donanemab. Leqembi is safe with its dosing and monitoring. If it wasn't, CMS registry would alert everyone.The benefit is questionable. The danger is real.
Probably why the company had exceeded expectations in patient starts!Wait till you see the "danger" of Donanemab. Leqembi is safe with its dosing and monitoring. If it wasn't, CMS registry would alert everyone.
Wait till you see the "danger" of Donanemab. Leqembi is safe with its dosing and monitoring. If it wasn't, CMS registry would alert everyone.
FYI - you are not anonymous on this post. One request for an IP address and your identity is revealed. Does slander mean anything to you? Go back to gym class.Alex Scott did the dude.
Really?FYI - you are not anonymous on this post. One request for an IP address and your identity is revealed. Does slander mean anything to you? Go back to gym class.
Really?
Cafepharma Policy:
"Per our policies, cafepharma does not record IP addresses with anonymous posts. So even with a subpoena or a court order, there is no information to provide on the origin of anonymous posts. We always recommend that you use a personal computer and personal internet connection to post"
Want extra protection? Use a VPN
